Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study

J. Panes,A. Dignass,G. Lichtenstein, K. H. Huang,M. Germinaro, N. Houck, C. Han,Y. Miao,H. Zhang, N. Abu Farsakh, B. Patel, D. Owczarek, T. Hisamatsu,B. Sands,B. Bressler

JOURNAL OF CROHNS & COLITIS(2024)

引用 0|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要